Qiagen acquired the enzyme solutions unit of Enzymatics in a deal that company officials said adds a “deep portfolio of capabilities to Qiagen’s strategy to offer a complete next generation sequencing (NGS) workflow from biological sample to valuable molecular insights as well as strengthens a broad and rapidly growing portfolio of `universal’ NGS products compatible with any sequencer.”

The Enzymatics portfolio that has been acquired will be commercialized globally through Qiagen’s direct, indirect, and OEM channels, noted Peer Schatz, Qiagen’s CEO.

“Enzymatics has distinguished itself as a premier enabler of the emergence of affordable, widely usable NGS sequencing”, he said. “These solutions are a perfect fit with our leading offering of universal NGS products as well as with our strategy to develop integrated workflows that will help to drive the adoption of NGS in clinical healthcare.”

Included in the transaction are R&D, manufacturing, formulation, and analytical capabilities which Qiagen points out will enhance the company’s expertise in enzymology. Approximately 50 employees have joined Qiagen at the current Enzymatics site in Beverly, MA. No financial terms were disclosed.

 








This site uses Akismet to reduce spam. Learn how your comment data is processed.